SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Vaccinex, Inc. (VCNX) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 30/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VCNX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio4.07
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-8.88
Book Value / Share$0.00
Revenue / Share$0.29
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-526.85 |
$316K |
$-13.94M |
-4412.3% |
| 2017 |
$-689.86 |
$90K |
$-18.72M |
-20802.2% |
| 2018 |
$-1,186.70 |
$724K |
$-29.52M |
-4077.1% |
| 2019 |
$-521.95 |
$523K |
$-32.02M |
-6121.4% |
| 2020 |
$-327.62 |
$50K |
$-29.31M |
-58618% |
| 2021 |
$-169.11 |
$900K |
$-23.23M |
-2581.3% |
| 2022 |
$-97.59 |
$100K |
$-19.72M |
-19722% |
| 2023 |
$-43.68 |
$570K |
$-20.25M |
-3552.8% |
| 2024 |
$-8.88 |
$601K |
$-18.63M |
-3100.5% |
